Supported by the findings of our meta-analysis, colchicine markedly raised the experimental group's risk of non-cardiovascular events (gastrointestinal symptoms, allergic reactions, etc.), and it was also more effective than the control group at preventing post-PCI stroke, in-stent thrombosis, and reducing post-operative hs-CRP and IL-6 levels. The gene discussed is IL6; the disease is Stroke.